IMPRINT
Pantarhei Bioscience BV | Boulevard 17 | 3707 BK Zeist | The Netherlands
Phone: +31 (0)30 6 985 020 | Email: info@pantarheibio.com
DISCLAIMER
The information contained in this website is for general information purposes only. The information is provided by Pantarhei Bioscience and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
SOCIAL MEDIA
© 2023
Last patient out in the phase II PCombi study with Estetrol in patients with prostate cancer
/in NewsOn May 14, 2020, the last patient has had his last study visit for the phase IIa clinical study of Pantarhei assessing the efficacy and safety of the fetal estrogen estetrol (E4) in prostate cancer patients. The study, the PCombi study, is a double-blind, randomised, placebo-controlled, multi-centre study in patients treated with hormone therapy, an luteinising hormone-releasing hormone (LHRH) agonist, for their prostate cancer.
The main objectives of this study are to evaluate the additional effect of E4 on testosterone suppression by the LHRH agonist as well as the prevention and treatment of hypoestrogenic side effects (e.g. hot flushes) due to the concomitant suppression of estrogens.
First results are expected to be available by beginning of August this year.
Pantarhei appoints Iman Schultz as new Director of Research & Development
/in NewsPer 1st of January 2020, Iman Schultz has joined Pantarhei as Director R&D. Iman will be responsible for the pre-clinical and clinical development of Pantarhei, including the coordination, analysis and scientific support of Pantarhei’s projects.
Yvette Zimmerman, CEO of Pantarhei states: “With the start of Iman, the company brings in 10 years of R&D experience in the field of biotechnology and drug development for oncological treatments, which will strengthen the company during further development of the projects.” Iman holds a PhD in Translation Oncology. Prior to joining Pantarhei he has been involved in oncology drug development as research scientist and project manager R&D at InteRNA Technologies BV, the Netherlands. In addition, Iman has valuable experience in the management of intellectual property (IP) support and securing financial support for different drug development companies.
Estetrol has DUAL efficacy in the treatment ofend-stage breast cancer
/in NewsThe pregnancy estrogen Estetrol (E4) has a DUAL effect when treating heavily-pre-treated women with advanced breast cancer who have no further treatment options. First, E4 has an anti-tumor effect and second, E4 improves wellbeing.
The Dutch biotech company Pantarhei Oncology presents on December 13, 2019 at the San Antonio Breast Cancer Symposium (SABCS) in the USA the results of the first clinical study with High Doses of the fetal estrogen Estetrol (HDE4) in women with advanced end-stage breast cancer. Nine women without further treatment options participated in the study and were treated with 20, 40 or 60 mg E4 per day for 12 weeks. Anti-tumor effects after 12 weeks treatment were confirmed in 5 of 9 women and strong improvement of wellbeing occurred in 7 of 9 patients.
For more information please read the Press Release or the Poster.
Voor meer informatie lees hier het Nederlandstalig persbericht.